{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T02:38:03Z","timestamp":1789699083487,"version":"4.0.1"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T00:00:00Z","timestamp":1732924800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.ejca.2024.115161","type":"journal-article","created":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T16:22:24Z","timestamp":1732983744000},"page":"115161","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11\/GNAQ mutant melanocytic tumors"],"prefix":"10.1016","volume":"214","author":[{"given":"Florentia","family":"Dimitriou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlana M.","family":"Orloff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica C.","family":"Koch Hein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phil F.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac F.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ester","family":"Simeone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamaneh","family":"Montazeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piyush","family":"Grover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inderjit","family":"Mehmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille L.","family":"Gerard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Gaudy-Marqueste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Jacques","family":"Grob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Michielin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omid","family":"Hamid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina V.","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Kapiteijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas B.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo A.","family":"Ascierto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony M.","family":"Joshua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard D.","family":"Carvajal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus O.","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica C.","family":"Hassel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Dummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejca.2024.115161_bib1","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41572-020-0158-0","article-title":"Uveal melanoma","volume":"6","author":"Jager","year":"2020","journal-title":"Nat Rev Dis Prim"},{"issue":"2","key":"10.1016\/j.ejca.2024.115161_bib2","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s41571-022-00714-1","article-title":"Advances in the clinical management of uveal melanoma","volume":"20","author":"Carvajal","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2024.115161_bib3","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1136\/bjophthalmol-2016-309034","article-title":"Metastatic disease from uveal melanoma: treatment options and future prospects","volume":"101","author":"Carvajal","year":"2017","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"10.1016\/j.ejca.2024.115161_bib4","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/CMR.0000000000000575","article-title":"Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis","volume":"29","author":"Rantala","year":"2019","journal-title":"Melanoma Res"},{"issue":"8","key":"10.1016\/j.ejca.2024.115161_bib5","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1093\/annonc\/mdz176","article-title":"Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study","volume":"30","author":"Khoja","year":"2019","journal-title":"Ann Oncol"},{"issue":"7229","key":"10.1016\/j.ejca.2024.115161_bib6","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/nature07586","article-title":"Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi","volume":"457","author":"Van Raamsdonk","year":"2009","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.ejca.2024.115161_bib7","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1001\/jamaophthalmol.2016.0903","article-title":"Driver mutations in uveal melanoma: associations with gene expression profile and patient outcomes","volume":"134","author":"Decatur","year":"2016","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"10.1016\/j.ejca.2024.115161_bib8","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000960","article-title":"Immune profiling of uveal melanoma identifies a potential signature associated with response to immunotherapy","volume":"8","author":"Qin","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2024.115161_bib9","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001501","article-title":"Comprehensive analysis of cutaneous and uveal melanoma liver metastases","volume":"8","author":"Hoefsmit","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"9","key":"10.1016\/j.ejca.2024.115161_bib10","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1158\/1078-0432.CCR-15-2294","article-title":"Identification of an immunogenic subset of metastatic uveal melanoma","volume":"22","author":"Rothermel","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.ejca.2024.115161_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0118564","article-title":"Phase II DeCOG-study of ipilimumab in pretreated and treatment-naive patients with metastatic uveal melanoma","volume":"10","author":"Zimmer","year":"2015","journal-title":"PLoS One"},{"issue":"20","key":"10.1016\/j.ejca.2024.115161_bib12","doi-asserted-by":"crossref","first-page":"3687","DOI":"10.1002\/cncr.28282","article-title":"Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience","volume":"119","author":"Luke","year":"2013","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.ejca.2024.115161_bib13","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/CMR.0000000000000744","article-title":"Nivolumab for metastatic uveal melanoma: a multicenter, retrospective study","volume":"31","author":"Tacar","year":"2021","journal-title":"Melanoma Res"},{"issue":"23","key":"10.1016\/j.ejca.2024.115161_bib14","doi-asserted-by":"crossref","first-page":"3917","DOI":"10.1200\/JCO.22.02199","article-title":"First-line, fixed-duration nivolumab plus ipilimumab followed by nivolumab in clinically diverse patient populations with unresectable stage III or IV melanoma: checkMate 401","volume":"41","author":"Dummer","year":"2023","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2024.115161_bib15","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1093\/annonc\/mdt376","article-title":"Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma","volume":"24","author":"Maio","year":"2013","journal-title":"Ann Oncol"},{"issue":"16","key":"10.1016\/j.ejca.2024.115161_bib16","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ejca.2024.115161_bib17","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1200\/JCO.20.00550","article-title":"Nivolumab plus ipilimumab for treatment-naive metastatic uveal melanoma: an open-label, multicenter, phase II trial by the Spanish multidisciplinary melanoma group (GEM-1402)","volume":"39","author":"Piulats","year":"2021","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2024.115161_bib18","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1200\/JCO.20.00605","article-title":"Nivolumab and ipilimumab in metastatic uveal melanoma: results from a single-arm phase II study","volume":"39","author":"Pelster","year":"2021","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.ejca.2024.115161_bib19","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","article-title":"Overall survival benefit with tebentafusp in metastatic uveal melanoma","volume":"385","author":"Nathan","year":"2021","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.ejca.2024.115161_bib20","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1056\/NEJMoa2304753","article-title":"Three-year overall survival with tebentafusp in metastatic uveal melanoma","volume":"389","author":"Hassel","year":"2023","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ejca.2024.115161_bib21","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1038\/s41591-022-02015-7","article-title":"Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial","volume":"28","author":"Carvajal","year":"2022","journal-title":"Nat Med"},{"issue":"22","key":"10.1016\/j.ejca.2024.115161_bib22","doi-asserted-by":"crossref","first-page":"5869","DOI":"10.1158\/1078-0432.CCR-20-1247","article-title":"Tebentafusp, a TCR\/anti-CD3 bispecific fusion protein targeting gp100, potently activated antitumor immune responses in patients with metastatic melanoma","volume":"26","author":"Middleton","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2024.115161_bib23","article-title":"Immuno-oncology approaches in uveal melanoma: tebentafusp and beyond","volume":"19","author":"Gerard","year":"2023","journal-title":"Immunooncol Technol"},{"issue":"6","key":"10.1016\/j.ejca.2024.115161_bib24","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-006747","article-title":"Tebentafusp in combination with durvalumab and\/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study","volume":"11","author":"Hamid","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2024.115161_bib25","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1146\/annurev-pathol-012513-104658","article-title":"The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia","volume":"9","author":"Bastian","year":"2014","journal-title":"Annu Rev Pathol"},{"issue":"2","key":"10.1016\/j.ejca.2024.115161_bib26","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2024.115161_bib28","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.ejca.2024.115161_bib29","doi-asserted-by":"crossref","DOI":"10.1177\/1758834018757175","article-title":"Treatment of uveal melanoma: where are we now?","volume":"10","author":"Yang","year":"2018","journal-title":"Ther Adv Med Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2024.115161_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11070971","article-title":"Tebentafusp: T cell redirection for the treatment of metastatic uveal melanoma","volume":"11","author":"Damato","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2024.115161_bib31","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231160140","article-title":"Tebentafusp: a first-in-class treatment for metastatic uveal melanoma","volume":"15","author":"Howlett","year":"2023","journal-title":"Ther Adv Med Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2024.115161_bib32","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00262-014-1525-z","article-title":"ImmTAC-redirected tumour cell killing induces and potentiates antigen cross-presentation by dendritic cells","volume":"63","author":"Bossi","year":"2014","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"10.1016\/j.ejca.2024.115161_bib33","first-page":"A909","article-title":"868\u2005Overall survival on tebentafusp in metastatic uveal melanoma (mUM) across the range of tumor gp100 expression levels","volume":"9","author":"Leach","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2024.115161_bib34","article-title":"Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysis","author":"Piulats","year":"2023","journal-title":"Ann Oncol"},{"issue":"17","key":"10.1016\/j.ejca.2024.115161_bib35","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1200\/JCO.21.01805","article-title":"Phase I study of safety, tolerability, and efficacy of tebentafusp using a step-up dosing regimen and expansion in patients with metastatic uveal melanoma","volume":"40","author":"Carvajal","year":"2022","journal-title":"J Clin Oncol"},{"issue":"13_ement","key":"10.1016\/j.ejca.2024.115161_bib36","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1158\/1538-7445.AM2021-517","article-title":"Abstract 517: tebentafusp induces transient systemic inflammation and modifies the micro-environment to sensitize uveal melanoma tumors to cytotoxic CD8 cells","volume":"81","author":"Butler","year":"2021","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.ejca.2024.115161_bib37","first-page":"A576","article-title":"546\u2005Results from phase Ib study of tebentafusp (tebe) in combination with durvalumab (durva) and\/or tremelimumab (treme) in metastatic cutaneous melanoma (mCM)","volume":"9","author":"Hamid","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2024.115161_bib38","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/CJI.0000000000000236","article-title":"Cytokine release syndrome during sequential treatment with immune checkpoint inhibitors and kinase inhibitors for metastatic melanoma","volume":"42","author":"Dimitriou","year":"2019","journal-title":"J Immunother"},{"key":"10.1016\/j.ejca.2024.115161_bib39","author":"Network","year":"2019"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924017684?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924017684?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T02:32:17Z","timestamp":1734402737000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804924017684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":38,"alternative-id":["S0959804924017684"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2024.115161","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11\/GNAQ mutant melanocytic tumors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.115161","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"115161"}}